GT601 / Grit Biotechnology - LARVOL DELTA

Next-generation neoantigen vaccines powered by AI-assisted discovery and APC-targeted delivery platforms (AACR 2025) - "Preclinical toxicology studies in multiple species have demonstrated favorable tolerability for both the ionizable lipid L52715 and the APC-targeted LNP formulation. Our lead neoantigen vaccine candidate, GT601, has successfully entered an investigator-initiated clinical trial in China, marking a major milestone in translating the NEOVigator platform into next-generation cancer immunotherapies."

IO biomarker • Tumor-specific neoantigens • Oncology • Solid Tumor

Trial in Progress: First in Human Study of GT601, a Next-Generation Neoantigen Cancer Vaccine for Hepatocellular Carcinoma (SITC 2025) - "GT601 will be administered intravenously between 8 to 12 weeks post-surgery, with timing determined by the investigator based on the participant's recovery status. The trial is currently open and enrolling patients."

First-in-human • P1 data • Tumor-specific neoantigens • Hepatocellular Cancer • Oncology • Solid Tumor